Skip to main content
Back to Peptides
Weight LossMetabolicFat Loss

Tirzepatide

Buy Now

Also known as: Mounjaro, Zepbound, GLP-1/GIP

Overview

Tirzepatide is a dual GIP/GLP-1 receptor agonist that provides even greater weight loss than semaglutide alone. It's the newest generation of incretin-based therapies, showing unprecedented results in clinical trials.

How It Works

Tirzepatide activates both GIP and GLP-1 receptors, providing synergistic effects on appetite suppression, insulin secretion, and glucose metabolism. The dual action leads to greater efficacy than single-receptor agonists.

Research Status

FDA approved as Mounjaro (diabetes) and Zepbound (obesity). SURMOUNT trials showed 20%+ weight loss.